Chemomab Therapeutics annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Free Cash Flow (FCF) History (CMMB)
Chemomab Therapeutics reported −$11.1M in free cash flow for fiscal 2025, an increase of $4.3M from the previous fiscal year.
View full Chemomab Therapeutics company overviewChemomab Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$11.1M | $4.3M | — | — |
| 2024 | 2024-12-31 | −$15.4M | $8.2M | — | — |
| 2023 | 2023-12-31 | −$23.6M | −$3.2M | — | — |
| 2022 | 2022-12-31 | −$20.4M | −$7.8M | — | — |
| 2021 | 2021-12-31 | −$12.6M | −$7.3M | — | — |
| 2020 | 2020-12-31 | −$5.3M | $11.3M | — | — |
| 2019 | 2019-12-31 | −$16.6M | −$2.1M | — | — |
| 2018 | 2018-12-31 | −$14.4M | −$5.9M | — | — |
| 2017 | 2017-12-31 | −$8.5M | −$4.7M | — | — |
| 2016 | 2016-12-31 | −$3.8M | — | — | — |
Chemomab Therapeutics quarterly free cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | −$7.5M | −$1.8M | — | — |
| Q1 2023 | 2023-03-31 | −$7.2M | −$3.5M | — | — |
| Q4 2022 | 2022-12-31 | −$5.7M | −$2.7M | — | — |
| Q3 2022 | 2022-09-30 | −$5.3M | −$2.7M | — | — |
| Q2 2022 | 2022-06-30 | −$5.7M | −$3,000 | — | — |
| Q1 2022 | 2022-03-31 | −$3.7M | −$2.4M | — | — |
| Q4 2021 | 2021-12-31 | −$3.0M | −$1.5M | — | — |
| Q3 2021 | 2021-09-30 | −$2.6M | −$1.7M | — | — |
| Q2 2021 | 2021-06-30 | −$5.7M | −$4.8M | — | — |
| Q1 2021 | 2021-03-31 | −$1.3M | $627,000 | — | — |
| Q4 2020 | 2020-12-31 | −$1.6M | $4.6M | — | — |
| Q3 2020 | 2020-09-30 | −$921,000 | $2.8M | — | — |
| Q2 2020 | 2020-06-30 | −$880,000 | $3.1M | — | — |
| Q1 2020 | 2020-03-31 | −$1.9M | $1.3M | — | — |
| Q4 2019 | 2019-12-31 | −$6.2M | — | — | — |
| Q3 2019 | 2019-09-30 | −$3.8M | — | — | — |
| Q2 2019 | 2019-06-30 | −$3.9M | — | — | — |
| Q1 2019 | 2019-03-31 | −$3.2M | — | — | — |
Chemomab Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$5.3M to −$11.1M, a net decrease of $5.9M. Chemomab Therapeutics's latest reported quarter, Q2 2023, generated −$7.5M in free cash flow, a decrease of $1.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Chemomab Therapeutics filings at SEC.gov ↗